Post-earnings recap
Reported
Thu, Aug 13, 2026
EPS actual
$-1.07
EPS est.
$-1.08
EPS surprise
+0.93%
1-day move
-5.95%
Celcuity Inc. reported a narrower loss per share than analysts expected, which is a positive sign. However, the stock fell by nearly 6%, indicating that investors may have been disappointed by the lack of revenue and guidance. The absence of management commentary could also contribute to uncertainty among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.07 | $-1.18 | +0.93% |
| Revenue | — | $7M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Celcuity Inc. is a biotechnology company focused on developing innovative treatments for cancer. With a market cap of $4 billion, it operates in the health care sector, which is increasingly important as advancements in medical technology and personalized medicine continue to grow.
Last quarter
In Q1-2026, Celcuity reported an EPS of $-0.86, beating expectations by nearly 20%. The stock reacted positively, gaining over 8% the following day.
Management promises and guidance
EPS beat streak
6Q
EPS beat rate
75%
Avg EPS surprise
+9.32%
Avg 1-day reaction
+1.56%
Analysts expect Celcuity to report a loss this quarter, but there is hope for a revenue surprise given the wide range of estimates.
Bull case
If Celcuity can exceed the EPS estimate and show stronger-than-expected revenue, it could signal growing market acceptance of its treatments.
Bear case
Conversely, if the company fails to meet expectations, it could raise concerns about its growth prospects and lead to a negative stock reaction.
Key metrics to watch
EPS
$-1.18Earnings per share is a key indicator of profitability and financial health, which investors closely monitor.
Revenue
$7MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will the EPS come in better than the consensus estimate of $-1.18?
A beat on EPS could indicate improved operational efficiency and investor confidence in the company's future.
Q2
What revenue figures will Celcuity report, especially in light of the $7M consensus?
Revenue performance will be crucial in assessing market demand for their products and overall business health.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±20.3%
Why consensus could be wrong
The Street may be underestimating Celcuity's potential for revenue growth due to its innovative treatment pipeline.
Supporting evidence
Previous quarters show a strong EPS beat rate of 75%, suggesting potential for positive surprises.
The wide range in revenue estimates indicates uncertainty that could work in Celcuity's favor if they outperform.
The options market is pricing in a significant move, suggesting that traders expect a more volatile outcome than consensus suggests.
Key risk
If revenue exceeds $10M, it could challenge the current bearish sentiment and shift market expectations.
Pre-commit to what would confirm each case.
This quarter's results will be critical in determining whether Celcuity can sustain its growth trajectory amid competitive pressures.
Bull confirmed if
An EPS of better than $-1.10 combined with revenue exceeding $10M would confirm the bull case.
Bear confirmed if
An EPS worse than $-1.25 and revenue below $5M would confirm the bear case.
What the market is pricing for the move.
Implied Move
±12.47%
Historical Avg
±4.5%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.
Options are pricing ±12.5% while CELC has averaged ±4.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
73.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Celcuity beats expectations, history suggests the stock could rise by around 3.4%, confirming positive market sentiment.
In line / cautious
If the results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
Should the company miss estimates, the stock could drop by about 2.4%, reflecting investor disappointment.
The lines on the call that would change the story.